{"id":40933,"date":"2013-10-18T08:01:31","date_gmt":"2013-10-18T12:01:31","guid":{"rendered":"http:\/\/1boringoldman.com\/?p=40933"},"modified":"2013-10-18T08:11:36","modified_gmt":"2013-10-18T12:11:36","slug":"follow-up-3","status":"publish","type":"post","link":"https:\/\/1boringoldman.com\/index.php\/2013\/10\/18\/follow-up-3\/","title":{"rendered":"follow-up&#8230;"},"content":{"rendered":"<div align=\"justify\">A couple of days ago, I posted this timeline of the SKB\/GSK&#8217;s studies of Paxil in adolescents [<a href=\"http:\/\/1boringoldman.com\/index.php\/2013\/10\/15\/paxil-in-adolescents-five-easy-pieces\/\" target=\"_blank\">paxil in adolescents: &ldquo;five easy pieces&rdquo;&hellip;<\/a>]:<\/div>\n<div align=\"center\"><img loading=\"lazy\" decoding=\"async\" width=\"348\" vspace=\"7\" height=\"311\" border=\"0\" src=\"http:\/\/1boringoldman.com\/images\/paxil-adolescent-1.gif\" \/><\/div>\n<div align=\"justify\">I wanted to put some index of their profits from the drug during the period between publishing Paxil Study 329 and the time the patent expired. I failed at that. I couldn&#8217;t even document the overall Paxil profitability. Subsequently, I found this: <\/div>\n<blockquote>\n<div align=\"center\" class=\"big\"><a target=\"_blank\" href=\"http:\/\/www.nytimes.com\/2012\/07\/03\/business\/glaxosmithkline-agrees-to-pay-3-billion-in-fraud-settlement.html?_r=0\">Glaxo Agrees to Pay $3 Billion in Fraud Settlement<\/a><\/div>\n<div align=\"center\" class=\"big\"><strong><font color=\"#200020\">New York Times<\/font><\/strong><\/div>\n<div align=\"center\" class=\"middle\">By KATIE THOMAS and MICHAEL S. SCHMIDT  <\/div>\n<div align=\"center\" class=\"small\">July 2, 2012<\/div>\n<p align=\"center\"><img decoding=\"async\" border=\"0\" src=\"http:\/\/1boringoldman.com\/images\/snip.gif\" \/><\/p>\n<p align=\"justify\">The three criminal charges involved Paxil, Wellbutrin and Avandia and  included a criminal fine of $1 billion. The remaining $2 billion  involves fines in connection with a civil settlement over the sales and  marketing practices of the blockbuster asthma drug Advair and several  other drugs.        <\/p>\n<p align=\"justify\"> Part of the civil settlement also includes claims that the company  overcharged the government for drugs. Glaxo did not admit any wrongdoing  in the civil settlement. Despite the large amount, $3 billion represents only a portion of what  Glaxo made on the drugs. Avandia, for example, racked up $10.4 billion  in sales, Paxil brought in $11.6 billion, and Wellbutrin sales were $5.9  billion during the years covered by the settlement, according to IMS  Health, a data group that consults for drugmakers.        <\/p>\n<p align=\"justify\"> &ldquo;So a $3 billion settlement for half a dozen drugs over 10 years can be  rationalized as the cost of doing business,&rdquo; Mr. Burns said&hellip;<\/p>\n<div align=\"center\"><img decoding=\"async\" border=\"0\" src=\"http:\/\/1boringoldman.com\/images\/snip.gif\" \/><\/div>\n<\/blockquote>\n<div align=\"justify\">Obviously these numbers aren&#8217;t exactly what I was looking for. They don&#8217;t tell us the profits from the off-label sales for adolescents. But I agree they are enough to support Patrick Burns conclusion that &ldquo;<em>a $3 billion settlement for half a dozen drugs over 10 years can be  rationalized as the cost of doing business<\/em>&rdquo;  [Burns was the spokesman for the whistle-blower advocacy group Taxpayers Against Fraud]. If profit is the index of success, it was worth it&#8230;<\/div>\n","protected":false},"excerpt":{"rendered":"<p>A couple of days ago, I posted this timeline of the SKB\/GSK&#8217;s studies of Paxil in adolescents [paxil in adolescents: &ldquo;five easy pieces&rdquo;&hellip;]: I wanted to put some index of their profits from the drug during the period between publishing Paxil Study 329 and the time the patent expired. I failed at that. I couldn&#8217;t [&hellip;]<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_bbp_topic_count":0,"_bbp_reply_count":0,"_bbp_total_topic_count":0,"_bbp_total_reply_count":0,"_bbp_voice_count":0,"_bbp_anonymous_reply_count":0,"_bbp_topic_count_hidden":0,"_bbp_reply_count_hidden":0,"_bbp_forum_subforum_count":0,"footnotes":""},"categories":[5],"tags":[],"class_list":["post-40933","post","type-post","status-publish","format-standard","hentry","category-opinion"],"_links":{"self":[{"href":"https:\/\/1boringoldman.com\/index.php\/wp-json\/wp\/v2\/posts\/40933","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/1boringoldman.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/1boringoldman.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/1boringoldman.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/1boringoldman.com\/index.php\/wp-json\/wp\/v2\/comments?post=40933"}],"version-history":[{"count":16,"href":"https:\/\/1boringoldman.com\/index.php\/wp-json\/wp\/v2\/posts\/40933\/revisions"}],"predecessor-version":[{"id":40949,"href":"https:\/\/1boringoldman.com\/index.php\/wp-json\/wp\/v2\/posts\/40933\/revisions\/40949"}],"wp:attachment":[{"href":"https:\/\/1boringoldman.com\/index.php\/wp-json\/wp\/v2\/media?parent=40933"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/1boringoldman.com\/index.php\/wp-json\/wp\/v2\/categories?post=40933"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/1boringoldman.com\/index.php\/wp-json\/wp\/v2\/tags?post=40933"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}